Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥(集 團)股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement regarding the Breakthrough Therapy Designation Granted to Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

17 August 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

  • for identification purposes only

Stock code: 600196

Stock abbreviation: Fosun Pharma

Announcement No.: Lin 2021- 112

Bond code: 143020

Bond abbreviation:17 Fosun 01

Bond code: 143422

Bond abbreviation:18 Fosun 01

Bond code: 155067

Bond abbreviation:18 Fosun 02

Bond code: 155068

Bond abbreviation:18 Fosun 03

Bond code: 175708

Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement regarding the Breakthrough Therapy Designation Granted to Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.*

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

  1. Overview

Pursuant to the public announcement made by the Center for Drug Evaluation under National Medical Products Administration (''NMPA''), the Axicabtagene Ciloleucel Injection ( 奕 凯 达 ®, the "Product") of Fosun Kite Biotechnology Co., Ltd.* (復星凱特生物科技有限公司)("Fosun Kite", a 50% equity interest of which is held by Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司), a subsidiary of the Company, as at the date of this announcement), an investee company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), has been granted breakthrough therapy designation for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (r/r iNHL) after two or more lines systemic therapy, including follicular lymphoma (FL) and marginal zone lymphoma (MZL).

1

II. Research Progress of the Product

The Product in the PRC is conducted following the technology transfer of the autologous CD19-directedCAR-T cell therapy (Yescarta®) of Kite Pharma ("Kite"), an operating company of Gilead Sciences, Inc. in the United States, and proposed to carry out localized production in China. On 10 June 2021, NMPA approved the Investigational New Drug of the Product for the treatment of relapsed or refractory indolent non- Hodgkin's lymphoma (r/r iNHL) after two or more lines of systemic therapy, including follicular lymphoma (FL) and marginal zone lymphoma (MZL). On 22 June 2021, NMPA approved the marketing registration of the Product for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-gradeB-cell lymphoma and DLBCL arising from follicular lymphoma.

As at the date of this announcement, no CAR-T cell therapy product has been approved for marketing in the PRC other than 奕凯达®.

As at the end of July 2021, the cumulative R&D investment of Fosun Kite for the Product was approximately RMB703.54 million (including patent and technology license fee, unaudited) at this stage.

III. Impact on the Company and Risk Warning

The Product is mainly subject to, among others, obtaining NDA approval before its commercialization can be carried out in the PRC for the indication under the breakthrough therapy designation. The inclusion in the breakthrough therapy designation will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of pharmaceutical products, the sale of the pharmaceutical products after launching to the market may be affected by factors including, among others, market conditions and sale channels, which will have greater uncertainty. Investors should be aware of the investment risks.

2

Announcement is hereby given.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. * 17 August 2021

* for identification purposes only

3

Attachments

  • Original document
  • Permalink

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 17 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2021 11:03:18 UTC.